NCT01787669View on ClinicalTrials.gov

Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

October 31, 2017

Conditions
DiabetesDiabetic Macular OedemaDiabetic Macular EdemaDiabetic Retinopathy
Interventions
DRUG

Avastin (Bevacizumab)

Avastin (Bevacizumab) administered intravitreally

DRUG

Ozurdex (dexamethasone)

Ozurdex (dexamethasone) given intravitreally

Trial Locations (3)

2000

Sydney Eye Hospital, Sydney

3002

Centre for Eye Research Australia (Royal Victorian Eye & Ear Hospital), Melbourne

6009

Lions Eye Institute, Perth

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

University of Sydney

OTHER

NCT01787669 - Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema | Biotech Hunter | Biotech Hunter